Researchers reported a shared genetic susceptibility of psoriasis and hidradenitis suppurativa, highlighting a need for ...

Conduit Pharmaceuticals (CDT) announces the filing of two groundbreaking patents for tapinarof, VTAMA, including a dual active cocrystal, ...

With the new manufacturing capacity, 100% of its key medicines for U.S. patients will be made in the U.S., Novartis said late ...

Johnson & Johnson (J&J) has reported data from the Phase III ICONIC-LEAD trial’s subgroup analysis evaluating icotrokinra in ...

Birmingham scientists have shown that a sequence of just three amino acids may reduce the severity of psoriasis, when applied topically in an emollient cream. The researchers, whose study is published ...

The MACE risk associated with initiating ustekinumab is comparable to that of adalimumab, etanercept, and secukinumab in patients with PsO or PsA.

Arcutis Biotherapeutics, Inc.’s ARQT share price has dipped by 11.05%, which has investors questioning if this is right time ...

New data presented at the 2025 World Congress of Pediatric Dermatology annual meeting highlights the efficacy and safety of ...

Icotrokinra appears to be an effective treatment for adolescent patients with moderate to severe plaque psoriasis, according to a subgroup analysis of the ICONIC-LEAD study.

Protagonist and Johnson & Johnson report positive Phase 3 data on icotrokinra in adolescent plaque psoriasis, showing high ...

Several characteristics, including BMI and Charlson Comorbidity Index, were associated with super response to biologics in patients with psoriasis.

Protagonist Therapeutics (PTGX) announced new icotrokinra data from a subgroup analysis of ICONIC-LEAD, the first ever Phase 3 registrational ...